knowledge -WSS

knowledge

author：fashion 2025-10-02 00:51:59 - browse：522

CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data from trials solely run in a single country such as China, but instead wants to see companies conducting studies across the world.

The comments by Richard Pazdur, director of the FDA’s Oncology Center of Excellence, came as more drugmakers report data from China, with Miami-based Summit Therapeutics earlier this week announcing that its investigational drug beat Merck’s blockbuster Keytruda in a head-to-head non-small cell lung cancer study in China.

It’s not a blanket policy, and the agency would assess each company’s submission to see how applicable the data are to the U.S. population, but in general, “I am pro multi-regional trials,” Pazdur said Friday at STAT@ASCO, STAT’s event at the American Society of Clinical Oncology annual meeting.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Public health communication lessons from Covid

explore

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

American Airlines has a tentative contract deal with its pilots. Southwest is still negotiating

UnitedHealth argues against case alleging wrongful AI care denials

Making the case for fair compensation in clinical trials

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Listen: A conversation with researcher Kevin Esvelt on biosecurity

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Bird flu surveillance in wastewater gets boost from consortium

Anesthesiologist group: stop taking Ozempic before surgery

Reports of telehealth's death have been greatly exaggerated

At least 13 dead in Texas as scorching temps continue

UnitedHealth argues against case alleging wrongful AI care denials

Psychedelics group wrestles with new pharma identity

Questions and answers about ramping up H5N1 bird flu vaccine

BioMarin wins approval for gene therapy to treat hemophilia A

Stoke drug shows lower activity against childhood epilepsy

focus

Trump allegedly attempted to have surveillance video deleted: Special Counsel

Ford recalls 870K F

An outrageous hospital charge: I paid $710 for an hour of babysitting

Ford recalls 870K F

Will biotech layoffs continue through 2023?

Biden to sign 'historic' executive order on how US military handles sexual assault cases

entertainment

explore

explore

explore